Physician profile
Jonathan S Cohen
NPI 1083699219
$3,116.90
in general payments reported to CMS, 2019-2025
24 companies · $201 in 2025
The $201 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,276 · 2020: $361 · 2021: $299 · 2022: $598 · 2023: $381 · 2025: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $583.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $582.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $575.41 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $471.93 | 2019-2023 | Ingrezza |
| Janssen Pharmaceuticals, INC | $361.93 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $219.10 | 2019-2023 | Rexulti |
| Lundbeck LLC | $169.02 | 2019-2023 | Rexulti |
| Allergan, INC. | $149.90 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $148.47 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $139.24 | 2019-2023 | Trintellix |
| Jazz Pharmaceuticals INC. | $104.57 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $102.94 | 2022-2023 | Qelbree |
| Neos Therapeutics, LP | $92.53 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $89.57 | 2019-2022 | |
| Abbvie INC. | $79.37 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $73.67 | 2020-2022 | |
| Shire North American Group INC | $59.18 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $56.74 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $53.27 | 2019 | |
| Almatica Pharma LLC | $33.56 | 2022-2023 | Loreev Xr |
| Alkermes, INC. | $33.02 | 2022 | |
| Bausch Health US, LLC | $29.56 | 2019-2020 | |
| Eisai INC. | $28.46 | 2021 | |
| Ironshore Pharmaceuticals INC. | $19.33 | 2023 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $13.37 | 2022 | |
| Adlon Therapeutics L.P. | $12.76 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.